Your email has been successfully added to our mailing list.

×
0.188524590163934 0.180327868852459 0.163934426229508 0.114754098360656 0.122950819672131 0.0601639344262296 0.0491803278688525 0.0565573770491805
Stock impact report

Bellerophon Announces FDA Agreement on Phase 2b Study Design for INOpulse® in Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Bellerophon Therapeutics, Inc. (BLPH) 
Last bellerophon therapeutics, inc. earnings: 4/6 10:23 am Check Earnings Report
US:NASDAQ Investor Relations: investors.bellerophon.com
Company Research Source: GlobeNewswire
WARREN, N.J., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced agreement with the U.S. Food and Drug Administration (FDA) on the Phase 2 study design for INOpulse® in pulmonary hypertension associated with Interstitial Lung Disease (ILD).  The Company met with the FDA in June 2017 to present positive results from its recently completed Phase 2a study in idiopathic pulmonary fibrosis (IPF), and to review clinical plans for its Phase 2b trial, entitled iNO-PF, in IPF as well as other pulmonary fibrosing diseases within ILD.  Subsequently, the Agency has accepted the Company’s proposed Phase 2b study design as well as an Investigational New Drug (IND) application to assess the effect of INOpulse on patients at both low and high risk for pulmonary hypertension associated with pulmonary fibrosis. The FDA recognized the dual mode of action of vasodilation and ventilation/perfusion matching of pulsed Show less Read more
Impact Snapshot
Event Time:
BLPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
BLPH alerts

from News Quantified
Opt-in for
BLPH alerts

from News Quantified